The 30 second version: The FDA's rule requires disclosure, not exclusion. Investigators (the doctors running the trial at their hospitals or clinics) tell the sponsor (biotechs or pharmas) about money that could bias a study, the sponsor tells the FDA, and the duty runs until 1 year after the study ends. If you're a clinical trial coordinator, you'll usually collect these forms rather than sign them. Written for coordinators who collect these forms, and for anyone training to be one.

In this file:

·        Why the FDA wants to know about an investigator's money

·        The 4 things the form asks about

·        Who signs one, and who usually doesn't

·        How long it follows an investigator, and what happens when it's missing

·        What happens when a would be PI owns $200,000 of the sponsor's stock

Dr. Reyes mentioned it the way people mention the weather. He'd joined an advisory board for the company sponsoring the study. One meeting a quarter, a modest honorarium. Nothing to do with the trial that they were being considered to run at their site.

"Then we’ll need to update this financial disclosure and call it out for consideration," Nani said.

"It's one meeting."

"It's one form."

Whether that honorarium ever reaches the FDA depends on the numbers, and that's the sponsor's call, not Nani's or Dr. Reyes's. What isn't anyone's call is whether the sponsor hears about it. Here's why.

The rule is 21 CFR Part 54. Its purpose is simple: the FDA can decide a study's data isn't adequate if nobody took steps to reduce bias, and an investigator's financial stake in the result is one possible source of bias. So when a company asks the FDA to approve a drug, it has to tell the FDA about the financial ties of the doctors who ran the studies it's relying on.

That last part matters. The rule covers the studies a company uses to show a drug works, and any study where one investigator makes a big contribution to showing it's safe. Early studies that only test tolerance or how the body handles a drug are generally not covered.

·        Pay that depends on the result. Anything worth more if the study turns out well: a bonus for a good outcome, payment in stock, royalties tied to sales.

·        A stake in the sponsor. Any ownership in a company whose shares don't have a public price, or more than $50,000 in a publicly traded sponsor. Your site's SOPs or IRB may set lower thresholds of their own.

·        A stake in the product. A patent, trademark, copyright or licensing deal on the thing being tested.

·        Other significant payments. Payments from the sponsor to the investigator or the institution worth more than $25,000 in total, not counting the cost of running studies: grants, equipment, retainers, honoraria.

Each of these counts the investigator's spouse and dependent children too. And the payments and stakes count while the investigator is working on the study and for 1 year after it ends.

The rule covers listed investigators and subinvestigators who are directly involved in treating or evaluating participants and influence endpoints of the study. The FDA's guidance says it isn't meant to include hospital staff such as nurses, residents, fellows and office staff who provide supporting care without a direct and significant contribution to the data, or people who only collect specimens or run routine tests.

So if you're a coordinator who isn't a listed subinvestigator, this is usually a form you collect, not one you sign. That's worth knowing the first time someone hands you a stack of them.

Not to the FDA, at least not from the site. Investigators give their information to the sponsor usually by way of the CRO if there is one. The FDA's 2013 guidance says the regulations don't prescribe a particular form for this, so sponsors use their own questionnaires. Then, when the company applies for approval, it sends the FDA either Form FDA 3454, certifying there's nothing to disclose, or Form FDA 3455, disclosing what there is and what it did to minimize bias.

It's also separate from the Form FDA 1572. The rules list them as different things the sponsor has to collect from an investigator before they start: the 1572 is the investigator's statement and commitments, and the financial information is its own item.

The sponsor has to collect the information before the investigator takes part. After that, the investigator has to promptly update it if anything relevant changes, during the study and for 1 year after it's complete. The FDA's guidance counts completion as the point when everyone is enrolled and the follow up for the main result is done.

That's why the requests keep coming. At many sites the forms are collected at activation with the 1572, CVs and licenses, requested again at close out, and once more about a year later. That schedule is common practice, not a rule, but it's how sponsors keep up with the 1 year tail.

Copy this: 6 casual mentions that mean an updated form. Listen for the casual mention.
A new consulting job. An advisory board. A speaking gig. Stock in the sponsor. A patent. A spouse who just started at the company.
Any of those usually means an updated form goes to the sponsor, even if it seems small. Deciding whether it's significant is the sponsor's job. Updating it is the investigator's obligation. Helping make sure the update reaches the sponsor is where the coordinator comes in. Check your site's SOP for who sends it.

Know someone starting their first coordinator job? Copy the 6 casual mentions and send them with one line: "It's one meeting. It's one form. Here's when a disclosure needs an update."

Dr. Reyes's honorarium is the easy case and sponsors can still choose not to include members of their advisory board due to the appearance of conflict of interest. Now let’s raise the stakes. Say a sponsor is choosing sites for a new study, and the doctor it wants as PI at one of them owns $200,000 of stock in that publicly traded sponsor. Nothing in federal law bars that doctor from the study. What happens instead is a series of checks, each run by a different group.

Step 1. The sponsor finds out before the doctor’s on the study. The sponsor has to collect their financial information before they take part (21 CFR 312.53(c)(4)). $200,000 is far past the $50,000 line for a public company, so it's a significant equity interest. The doctor’s spouse's and dependent children's holdings would count too. The clock covers the time they’re on the study and 1 year after it, so stock sold before the doctor agrees to take part falls outside the window. That's why one common outcome of this conversation is a sale.

Step 2. The sponsor decides, knowing it will have to explain itself. Part 54 doesn't forbid choosing that doctor with the financial interest, but it creates work. If this is a study the company will rely on to show the drug works, it will have to disclose their stake to the FDA on Form 3455, and that form asks for more than a dollar amount. Under 21 CFR 54.4(a)(3)(v), the company has to describe "any steps taken to minimize the potential for bias" from the interest. And the FDA can refuse to even file an application that's missing the required financial information.

The rule doesn't list what those steps have to be. In practice, the protections sponsors describe tend to look like these:

·        Blinding, so neither the doctor with the financial interest nor their staff know who is getting the study drug.

·        An independent committee, not the site, judging the key results.

·        Enough other sites that one investigator's data can't drive the outcome.

·        Closer monitoring of their site.

·        A smaller role for them, or a different PI.

Plenty of sponsors simply pick another doctor rather than carry a Form 3455 on a study that matters for approval. That's a business call, not a rule. And if the study only tests how the body handles the drug, Part 54 generally doesn't apply at all.

Step 3. The doctor's own institution and the IRB weigh in. This is usually where "you can't be the PI" comes from. In 2001, the Association of American Medical Colleges recommended a rebuttable presumption. That's a starting rule that can be overturned: someone with a significant financial interest in a study shouldn't conduct it unless the circumstances are compelling. Being uniquely qualified, and needed for the study to run safely, is the classic example. A 2008 report written with the Association of American Universities pushed institutions to put that into practice. One university system's policy, for example, says a person with a financial interest in a proposed clinical study "may not conduct that research" unless there are compelling circumstances and its conflicts committee approves. Even then, it requires disclosure to participants and outside monitoring.

If the study has NIH or other Public Health Service funding, the rule lists what an institution can require to manage a conflict: telling participants, an independent monitor, changing the research plan or who does what, removing someone from all or part of the research, selling the stock, or ending the relationship.

At many institutions, the study waits on the conflicts committee before the IRB signs off, and that's the part coordinators actually see. The answer can be a different PI, a smaller role, an outside monitor, or a stock sale. If the doctor practices outside a university and the study uses a central or commercial IRB, there may be no conflicts committee at all, and the checks come down to the sponsor, the IRB's own questions and the FDA.

The IRB has its own conflict rule too. Under 21 CFR 56.107(e), a board member with a conflicting interest can't take part in reviewing that study, except to give information the board asks for.

Step 4. The FDA weighs it at approval. The last check inevitably comes years later, when the company applies for approval. The FDA looks at the size and nature of each disclosed interest and the steps the company says it took to reduce bias.

If the FDA has a serious question about the data, it can audit the data from that investigator, ask the company for more analyses, ask for an independent study, or decide not to rely on that study at all. That last option is the real risk to a sponsor, and it's why these decisions get made during site selection, not after. The company has to keep the records for 2 years after approval.

Imagine a scenario where a study is only run at 5 sites, and 4 of the doctors own $300,000 in stock of the company running the trial. Scenarios like that are exactly what these rules exist to catch. In 2009, the HHS Inspector General looked at the FDA's oversight of this information and found gaps. 42% of the approved applications it reviewed were missing financial information. FDA reviewers didn't document a review of the information for 31% of them. And for 20% of the applications that did disclose interests, neither the FDA nor the company took any action. The report's recommendation to collect this information earlier, before trials start, is still listed as open as of November 2026. The FDA issued its current guidance on these forms in 2013.

The FDA's own paperwork estimate puts the site side of this at about 13,646 investigators a year, at roughly 10 minutes each. It's a small form and it's one of the few places federal rules ask a trial doctor directly about money.

·        Financial disclosure exists because an investigator's money is a possible source of bias. 21 CFR Part 54 lets the FDA weigh it when deciding whether to rely on a study.

·        The form asks about 4 things: pay tied to the result, a stake in the sponsor, a stake in the product, and other sponsor payments over $25,000. A spouse's and dependent children's count too.

·        It covers the study and 1 year after. Investigators report to the sponsor, and the sponsor reports to the FDA on Form 3454 or 3455.

·        The FDA's rule requires disclosure, not exclusion. When a stake is large, it's usually the institution's conflicts committee that limits the investigator's role.

·        Coordinators who aren't listed subinvestigators usually collect these forms rather than sign them. The most useful thing you can do is notice when something changes.

Dr. Reyes's advisory board took one form and about 10 minutes. Nani had it on its way to the sponsor before lunch.

Reply to this email or leave a comment on the newsletter: coordinators, what's the hardest part of keeping financial disclosures current? Chasing a subinvestigator who left? Explaining why it matters? Every query gets read, and the best ones get answered in a future issue.

Know someone training for their first coordinator job? Send them this with one line: "The FDA's rule requires disclosure, not exclusion. Here's what the form asks and who reads it." Use your referral link below so the share counts. The Open Site File is written for exactly that person.

The Open Site File is one part of Root to Rx, and we all work toward the same thing: making clinical research easier to understand and harder to misrepresent. Wednesday, Plain Talk opens in The Root Room, where a real health claim tries to work on someone, then takes it apart in plain language, with the receipts. Sunday, The Roots, on LinkedIn and Substack, is a letter for the people whose family treats them as the medical desk. And every Tuesday, The Open Site File shows you the inside of the site, where the people who make trials run actually work. Different doors, one mission: more people who understand how medicine gets made, and fewer people misled about it.

·        Previous issue: Issue 21, CRA, MSL or drug rep

·        Related: Issue 19, what a clinical research assistant does, and the 1572

·        For the people whose family treats them as the medical desk: The Roots, our weekly letter.

·        New to the field? Scroll the Sci Comm Map from lab idea to pharmacy shelf and meet the people who explain each step, then open its directory and filter by the topic you want to work in, like oncology or vaccines. Following a few of them is a quick way to learn the language before your first interview.

·        Why the rules read the way they do, and the history behind them: Version History.

·        Helping a patient or family member look for a study? A walkthrough of the public trial registries.

·        Patient materials, including a medication and supplement log modeled on the conmed logs used in trials: the Root to Rx shop.

·        21 CFR 54.4, Certification and disclosure requirements (eCFR)

·        21 CFR Part 54, Financial Disclosure by Clinical Investigators (eCFR)

·        21 CFR 312 Subpart D, including 312.53(c) and 312.64(d) (eCFR)

·        FDA, Financial Disclosure by Clinical Investigators. Final guidance, February 2013

·        FDA, IDE Financial Disclosure

·        Federal Register notice on financial disclosure burden estimates, 1 May 2025 (docket FDA-2024-N-4754)

·        HHS OIG, The Food and Drug Administration's Oversight of Clinical Investigators' Financial Information, OEI-05-07-00730, January 2009

·        42 CFR 50 Subpart F, Promoting Objectivity in Research (eCFR)

·        21 CFR 56.107, IRB membership (eCFR)

·        AAMC, Protecting Subjects, Preserving Trust, Promoting Progress: Policy and Guidelines for the Oversight of Individual Financial Interests in Human Subjects Research, December 2001

·        AAMC and AAU, Protecting Patients, Preserving Integrity, Advancing Health: Accelerating the Implementation of COI Policies in Human Subjects Research, February 2008

·        University of Massachusetts, Guidelines and Procedures for the Oversight of Individual and Institutional Financial Interest in Human Subject Research

·        42 CFR 50.605, Management and reporting of financial conflicts of interest (eCFR)

•  •  •

The Open Site File is general education about how clinical research sites work. It is not regulatory, legal, or medical advice, and it is not tied to any specific study, sponsor, or employer. If you are in a trial, your study team and your own doctor are the right people to ask about your situation. Always follow your own site’s SOPs, your protocol, and your PI and QA team. Names and characters are invented composites.

Disclosure: The Open Site File is part of Root to Rx, published independently by Open Label Media LLC. Views expressed are personal views of Justin Yamashita and do not represent his employer or any affiliated organization. No employer resources or proprietary information are used. Every claim is sourced from publicly available materials.

Filed by Justin Yamashita, MSc., Open Label Media